<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02310347</url>
  </required_header>
  <id_info>
    <org_study_id>S54673</org_study_id>
    <secondary_id>2012-003017-33</secondary_id>
    <nct_id>NCT02310347</nct_id>
  </id_info>
  <brief_title>Influence of a Medicinal Cannabinoid Agonist on Responses to Food Images and Food Intake</brief_title>
  <official_title>Influence of a Medicinal Cannabinoid Agonist on Behavioural Responses to Food Images and Food Intake: Role of Gut Peptides</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universitaire Ziekenhuizen Leuven</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Universitaire Ziekenhuizen Leuven</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to examine the influence of a medicinal cannabinoid agonist&#xD;
      versus placebo on behavioural and gut peptide responses to food images and food intake.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>December 2014</start_date>
  <completion_date type="Anticipated">April 2017</completion_date>
  <primary_completion_date type="Actual">September 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Behavioural responses to food images and food intake</measure>
    <time_frame>2 years</time_frame>
    <description>Scores on Visual Analogue Scales</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Gut peptide responses</measure>
    <time_frame>2 years</time_frame>
    <description>Concentrations of gut peptide levels will be determined using radioimmunoassays</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">18</enrollment>
  <condition>Appetite Regulation</condition>
  <arm_group>
    <arm_group_label>Marinol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>generic name: dronabinol&#xD;
dosage: 0.1 mg/kg&#xD;
frequency: 2 times a single dose&#xD;
duration: acute adminstration</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Empty hard gelatin capsules</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>dronabinol</intervention_name>
    <arm_group_label>Marinol</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        For healthy volunteers:&#xD;
&#xD;
          1. 20 ≤ BMI ≤ 25&#xD;
&#xD;
          2. Age 18-60&#xD;
&#xD;
          3. Right handed&#xD;
&#xD;
          4. Stable body weight for at least 3 consecutive months at start of study and no history&#xD;
             of behavioural, therapeutic or surgical treatment aiming at or leading to weight&#xD;
             loss/gain&#xD;
&#xD;
        For obese subjects:&#xD;
&#xD;
          1. BMI &gt; 30&#xD;
&#xD;
          2. Age 18-60&#xD;
&#xD;
          3. Right handed&#xD;
&#xD;
          4. Stable body weight for at least 3 consecutive months at start of the study and no&#xD;
             behavioural, therapeutic or surgical treatment aiming at or leading to weight&#xD;
             loss/gain for at least 3 consecutive months&#xD;
&#xD;
        For FD patients:&#xD;
&#xD;
          1. FD diagnosis according to 'Rome III' criteria&#xD;
&#xD;
          2. Age 18-60&#xD;
&#xD;
          3. Right handed&#xD;
&#xD;
          4. 5% weight loss since onset of symptoms&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Medical conditions (current or history):&#xD;
&#xD;
               -  Abdominal/thoracic surgery except appendectomy&#xD;
&#xD;
               -  Gastrointestinal, endocrine (especially diabetes), or neurological diseases&#xD;
&#xD;
               -  Cardiovascular, respiratory, renal or urinary diseases&#xD;
&#xD;
               -  Hypertension&#xD;
&#xD;
               -  Food or drug allergies&#xD;
&#xD;
               -  Head trauma with loss of consciousness&#xD;
&#xD;
          2. Psychiatric disorders:&#xD;
&#xD;
               -  Eating disorders&#xD;
&#xD;
               -  Psychotic disorders&#xD;
&#xD;
               -  Major depressive disorder&#xD;
&#xD;
               -  Somatoform disorder&#xD;
&#xD;
          3. Medication use:&#xD;
&#xD;
               -  No history of cannabis use or any other drug of abuse for at least 12 months&#xD;
                  prior to the study&#xD;
&#xD;
               -  All medication except oral contraception;&#xD;
&#xD;
          4. Known allergy to dronabinol and/or sesam oil&#xD;
&#xD;
          5. Pregnancy, plans to conceive or refusal to take adequate precaution to avoid pregnancy&#xD;
&#xD;
          6. Subjects who refuse to abstain from driving during the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lukas Van Oudenhove, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospitals Leuven, campus Gasthuisberg</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Hospitals Leuven, campus Gasthuisberg</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>October 2016</verification_date>
  <study_first_submitted>November 19, 2014</study_first_submitted>
  <study_first_submitted_qc>December 3, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 8, 2014</study_first_posted>
  <last_update_submitted>October 25, 2016</last_update_submitted>
  <last_update_submitted_qc>October 25, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 26, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dronabinol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

